Yes, yourself tends to be your biggest enemy in this game.
Without sounding like I'm trying to justify my reason for selling RMD have you got any thoughts on some of the negatives I have interpreted from the results (not saying my view is correct).
1. A small increase in gross margins through internal efficiencies is actually masking a decline in average selling prices.
2. What seems to be a decent increase in total operating expenses. This figure does include a couple of one offs (acquisition and litigation expenses) but SGA and R&D costs have had decent increases.
3. Decrease in EPS
Note: I'm not trying to downramp or do anything sinister, just want input into what I see as possible negatives. Any thoughts on the above?
Warrigals
Ann: ResMed Announces Results for the Second Qtr of FY 2017, page-7
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RMD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$37.28 |
Change
0.200(0.54%) |
Mkt cap ! $22.38B | |||
| Open | High | Low | Value | Volume |
| $37.50 | $37.55 | $37.15 | $17.93M | 480.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3363 | $37.27 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $37.30 | 1001 | 2 |
View Market Depth
| Last trade - 16.10pm 22/11/2024 (20 minute delay) ? |
| RMD (ASX) Chart |
